Norditropin NordiFlex Drug Interactions

Concomitant treatment with glucocorticoids inhibits the growth-promoting effect of Norditropin. Patients with ACTH deficiency should have their glucocorticoid replacement therapy carefully adjusted to avoid any inhibitory effect on growth.
Growth hormone decreases the conversion of cortisone to cortisol and may unmask previously undiscovered central hypoadrenalism or render low glucocorticoid replacement doses ineffective (see Precautions).
In women on oral oestrogen replacement, a higher dose of growth hormone may be required to achieve the treatment goal (see Precautions).
Data from an interaction study performed in growth hormone deficient adults suggest that somatropin administration may increase the clearance of compounds known to be metabolised by cytochrome P450 isoenzymes. The clearance of compounds metabolised by cytochrome P450 3A4 (e.g. sex steroids, corticosteroids, anticonvulsants and cyclosporine) may be especially increased resulting in lower plasma levels of these compounds. The clinical significance of this is unknown.
The effect of somatropin on final height can also be influenced by additional therapy with other hormones, e.g. gonadotropin, anabolic steroids, oestrogen and thyroid hormone.
In insulin treated patients adjustment of insulin dose may be needed after initiation of somatropin treatment (see Precautions).
Paediatric population: Interaction studies have only been performed in adults.